Detalhe da pesquisa
1.
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Cancer
; 123(19): 3843-3854, 2017 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28558150
2.
Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma.
Mol Carcinog
; 52(5): 377-86, 2013 May.
Artigo
Inglês
| MEDLINE | ID: mdl-22213339
3.
Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.
Tumour Biol
; 34(5): 2781-9, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23686785
4.
Pharmacokinetics of Dacarbazine and Unesbulin and CYP1A2-Mediated Drug Interactions in Patients With Leiomyosarcoma.
Clin Transl Sci
; 2023 Dec 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38129988
5.
Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
Prostate
; 72(15): 1648-58, 2012 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-22473873
6.
Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats.
Invest New Drugs
; 30(3): 853-61, 2012 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-21197621
7.
Environmental factors in causing human cancers: emphasis on tumorigenesis.
Tumour Biol
; 33(5): 1265-74, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-22614680
8.
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
J Clin Oncol
; 35(24): 2790-2797, 2017 Aug 20.
Artigo
Inglês
| MEDLINE | ID: mdl-28548889
9.
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
J Clin Oncol
; 35(19): 2141-2148, 2017 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28291390
10.
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
Clin Cancer Res
; 23(19): 5711-5719, 2017 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28679770
11.
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
Clin Cancer Res
; 21(17): 3870-8, 2015 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-25944802
12.
Delivery of tea polyphenols to the oral cavity by green tea leaves and black tea extract.
Cancer Epidemiol Biomarkers Prev
; 13(1): 132-7, 2004 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-14744744
13.
Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability.
Cancer Epidemiol Biomarkers Prev
; 11(10 Pt 1): 1025-32, 2002 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-12376503
14.
Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice.
J Agric Food Chem
; 52(4): 935-42, 2004 Feb 25.
Artigo
Inglês
| MEDLINE | ID: mdl-14969553
15.
Expression of specificity protein transcription factors in pancreatic cancer and their association in prognosis and therapy.
Curr Med Chem
; 19(22): 3779-86, 2012.
Artigo
Inglês
| MEDLINE | ID: mdl-22725697
16.
Tolfenamic acid suppresses cytochrome P450 2E1 expression in mouse liver.
Integr Biol (Camb)
; 4(9): 1122-9, 2012 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-22832660
17.
Relevance of drug metabolizing enzyme activity modulation by tea polyphenols in the inhibition of esophageal tumorigenesis.
Med Chem
; 7(5): 480-7, 2011 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-21801144
18.
Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative study.
Exp Ther Med
; 1(2): 307-311, 2010 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-22993543
19.
Inhibition of carcinogenesis by tea.
Annu Rev Pharmacol Toxicol
; 42: 25-54, 2002.
Artigo
Inglês
| MEDLINE | ID: mdl-11807163